News | Ultrasound Imaging | October 19, 2017

Study of over 200 patients found CEUS achieve correct diagnosis with 97 percent accuracy, without radiation and at lower cost

Contrast-Enhanced Ultrasound Safe and Effective Detector of Liver Cancer

October 19, 2017 — Doctors can effectively detect liver cancer with ultrasound and tiny microbubbles, according to a study announced at the International Contrast Ultrasound Society (ICUS) 32nd Annual Conference, Oct. 5-6 in Chicago. This technique allows detection without radiation, expensive magnetic resonance imaging (MRI) equipment or biopsies.

The imaging technique, known as contrast-enhanced ultrasound (CEUS), "is an exciting option because it provides a more cost-effective and less-invasive way for accurately characterizing the tumor," said Stephanie Wilson, M.D., a professor of radiology at the University of Calgary and study author.

The study of over 200 patients at risk for hepatocellular carcinoma, the most common liver cancer and the second leading cause of cancer deaths worldwide, found that CEUS imaging using the microbubbles allowed for the correct diagnosis with 97 percent accuracy.

CEUS uses liquid suspensions of tiny gas microbubbles to improve the clarity and reliability of an ultrasound image. The microbubbles are smaller than red blood cells and, when they are injected into a patient's arm vein, they flow through the microcirculation and reflect ultrasound signals, improving the accuracy of diagnostic ultrasound exams. The microbubbles are expelled from the body within minutes.

Steven Feinstein, M.D., a professor of medicine at Rush University in Chicago, said the study validates the vast benefits of using microbubble ultrasound contrast agents as a safe, convenient and effective diagnostic imaging tool. "The findings are extremely exciting and demonstrate that CEUS imaging improves patient care without exposing individuals to tissue diagnosis or ionizing radiation,” Feinstein added.

Wilson’s study utilized the Liver Imaging Reporting and Data System (LI-RADS), a tool radiologists use to classify liver tumors using computed tomography (CT), MR and CEUS imaging in patients with suspected liver cancer. Additional prospective studies are expected according to Yuko Kono, M.D., a professor of hepatology and gastroenterology at the University of California San Diego and a leader in the CEUS imaging field.

For more information: www.icus-society.org


Related Content

News | Artificial Intelligence

April 16, 2025 — An artificial intelligence (AI) program trained to review images from a common medical test can detect ...

Time April 16, 2025
arrow
News | Ultrasound Women's Health

April 11, 2025 — Contrast-enhanced ultrasound (CEUS) is a safe and accurate diagnostic imaging option for pregnant women ...

Time April 11, 2025
arrow
News | Focused Ultrasound Therapy

March 31, 2025 — Neuropathic pain affects up to 10 percent of the global population and can be challenging to manage ...

Time April 02, 2025
arrow
News | Breast Imaging

March 20, 2025 — GE HealthCare has launched Invenia Automated Breast Ultrasound (ABUS) Premium, the latest 3D ultrasound ...

Time March 21, 2025
arrow
News | X-Ray

March 18, 2025 — GE HealthCare recently announced a collaboration with NVIDIA expanding the existing relationship ...

Time March 19, 2025
arrow
News | Breast Imaging

Feb. 26, 2025 — iCAD, Inc. a provider of clinically proven AI-powered cancer detection solutions, and Koios Medical, a ...

Time March 03, 2025
arrow
News | Focused Ultrasound Therapy

Jan. 8, 2025 - EDAP TMS SA, a supplier of robotic energy-based therapies, has announced that the first patient has been ...

Time January 08, 2025
arrow
News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
News | Radiology Business

July 19, 2024 — GE HealthCare announced it has entered into an agreement to acquire Intelligent Ultrasound Group PLC’s ...

Time July 19, 2024
arrow
Feature | Women's Health | By Jordan Bazinsky

Investing in women’s health should not merely be a metric on the equity dashboard — it should drive policy and tactical ...

Time July 08, 2024
arrow
Subscribe Now